IVIXF (Invion) Total Equity: $3.79 Mil (As of Dec. 2025)


IVIXF Invion Ltd IVIXF
16 GF Score
Price $0.04
GF Value $0.17
! 2 Warning Signs
View Full Analysis

What is Invion Total Equity?

Invion IVIXF -83.23% 16 Total Equity is $3.79 Mil as of Dec. 2025. GuruFocus rates IVIXF with a GF Score™ of 16/100 and a GF Value™ of $0.17. The stock has 2 warning signs investors should review.

Invion's total equity for the quarter that ended in Dec. 2025 was $3.79 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Invion Total Equity Historical Data

* Premium members only.

The historical data trend for Invion's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invion Total Equity Chart

Invion Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.66 13.76 12.35 9.59 5.37

Invion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.95 9.59 8.32 5.37 3.79
IVIXF
16GF Score
Invion Ltd IVIXF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invion Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Invion's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=6.178-0.806
=5.37

Invion's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=5.374-1.583
=3.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $3.79 Mil mean?
Invion (IVIXF) has a Total Equity of $3.79 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Invion and its competitors.
Is Invion's Total Equity too high?
Invion's current Total Equity is $3.79 Mil. Overall, Invion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Invion's Total Equity compare to ZTS and UTHR?
Invion's Total Equity of $3.79 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Invion and its competitors. Invion's current Total Equity is $3.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Invion (IVIXF) has a current Total Equity of $3.79 Mil. The stock's GF Value™ is $0.17, compared to a current price of $0.04 — trading 78.3% below its estimated fair value. The current Total Equity is $3.79 Mil. Invion's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Invion (IVIXF), the current Total Equity is $3.79 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Invion (IVIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Invion stock appears to be undervalued. The current stock price of $0.04 is trading 78.3% below its estimated GF Value™ of $0.17.

Key valuation signals for IVIXF:

  • Total Equity: $3.79 Mil
  • GF Value™: $0.17 vs. price of $0.04 (78.3% below fair value)
  • GF Score™: 16/100 with 2 warning signs

No single metric tells the full story. See the IVIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Invion Business Description

Other Exchanges 7C8:GermanyIVX:Australia
Address 692 High Street, East Kew, VIC, AUS, 3102
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
16GF Score

Get the complete analysis for IVIXF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price
$0.17
GF Value